Stasis ulcers are commonly the result of chronic venous insufficiency. We have recently assessed 15 patients with stasis ulcers that failed to heal after one year of routine wound care. All patients demonstrated a defect in hemostasis,
and a biopsy revealed livido vasculitis. Eleven of fifteen patients were treated with clopidogrel and dalteparin, and 4 of 15 patients were treated with clopidogrel alone. Thirteen of fifteen patients (86.6%) completely healed within three months of starting antithrombotic therapy. Patients with stasis ulcers and chronic venous insufficiency who fail to heal with routine wound care should be subjected to biopsy, a procoagulant defect evaluation, and initiation of clopidogrel and dalteparin therapy if a defect is found.
Stasis ulcers are most commonly the result of chronic venous insufficiency resulting from severe or recurrent deep vein thrombosis (DVT) of the lower extremities.
However, they may also arise from severe varicosities, chronic ankle edema, marked obesity, diabetes, arteriovenous fistulae, and other causes. Management of stasis ulcers generally consists of edema control, compression, vigorous wound care, and antibiotic therapy. Some patients are, however, refractory to therapy. One of the authors (R. Scott), director of a large wound care center, began referring patients for hemostasis evaluation to rule out blood coagulation proteir/platelet defects associated with hypercoagulability and thrombosis/microvascular thrombosis to account for nonhealing of stasis ulcers, after these patients failed to heal with routine treatment for more than 1 year. All of these patients had periulcer biopsies revealing livido vasculitis. We have now seen 26 such patients, all of whom have been found to have a ' hypercoagulable blood coagulation protein/platelet defect to account for microvascular thrombosis, which prevented adequate wound healing. We herein report the results of the first 15 patients because they were assessed and followed to healing before availability of a computer program that standardized wound measurement parameters. The first 5 patients were measured by manual methods of consistent evaluators (case managers), adhering to a standardized measurement protocol. A subsequent publication will summarize all the patients seen to date.
MATERIALS AND METHODS

Patient population
All patients were referred from the Wound Care Center after noting both nonhealing of the stasis ulcers for ± 1 2 months of standardized wound care and a biopsy, interpreted by a dermatopathologist, that demonstrated livido vasculitis. The 3.0-mm punch biopsies were taken' from an area adjacent to the wound. After hematologic referral, patients were subjected to a thorough history and physical examination and were assessed for blood coagulation protein/platelet defects associated with hypercoagulability and thrombosis/microvascular thrombosis or immune vasculitis.
Treatment regimens
If a defect was found, as was the case in all patients thus far studied, they were placed on 75 mg/day of clopidogrel for a period of 2 to 4 weeks and were assessed by the wound care team. If substantial accelerated healing was noted on clopidogrel alone (4 of 15 patients), only ~Ic~pi~c~gr~1 was used. If healing was not noted or if healing was not substantially improved, dalteparin at 5;(~~~ anti-Xa units every 24 hours, by subcutaneous injection, was added to the clopidogrel regimen ~I of 15 patients). Patients were evaluated by the wound care team for wound measurements, photographed every 2 weeks, and assessed by monitoring hemostasis parameters weekly for the first 4 weeks and then every 2 weeks thereafter; hemostasis evaluation consisted of only complete blood count (CBC) for the clopidogrel patients and CBC plus low-molecular-weight heparin assay (anti-Xa method) for patients on clopidogrel and dalt~Iaarin. After complete healing, dalteparin was stopped 30 days later and clopidogrel was stopped 60 days later.
All patients were also instructed to perform antiembolic exercises. Patients were shown antiembohc leg exercises consisting of dorsi-plantar flexion of each foot with the legs supported at the feet, straight, and elevated above the hips. These exercises were to continue for 3 to 5 minutes or until the calf muscle group was fatigued, as indicated by initiation of muscle pain. The opposite leg is then to be exercised in a similar manner. Patients were instructed to do these exercises 4 to 6 times a day. Patients were also instructed to not remain in a sitting position or indulge in other activities, such as automobile or airplane trips, with the thighs or knees bent, for more than 20 minutes at a time without straightening the legs through ambulation or leg stretching for a few minutes.
Laboratory evaluation
The blood protein/platelet defect assays performed in panel I consisted of prothrombin time and activated partial thromboplastin time by routine techniques (I) on the ACL 3000; anticardiolipin antibodies (IgG, IaA, and IgM idiotypes) by solid phase ELISA (2,3); lupus anticoagulant (with phospholipid confirmation if positive) by the Russell viper venom time (dRVVT) assay (3-5); antiphospholipid subgroups, consisting of antiphosphatidylseine (IgG, IgA, and IgM), antiphosphatidylethanolamine (IgG, IgA, and IgM), antiphosphatidylinositol (IgG, IgA, and IgM), antiphosphat.idylcholine (1c,,G, IgA, and IgM), antiphosphatidylglycerol (IgG, IgA, and IgM), and antiphosphatidic acid ~I~Cip IgA, and IgM), by methods described by Toschi (6) ; beta-2-glycoprotein-1 (7) , hexagonal phospholipid (8) , and functional protein S (9), followed by a protein S panel of immunologic (total) (10) and free protein S 11 ) and C4b-binding protein (12) if the functional protein S level was abnonmally low; protein C assay by chromogenic technique (13); factor XIII by immunoassay (14) and function (15) antithrombin assay by chromogenic technique (16) ; sticky platelet syndrome assay by the method of Mammen (17) ; activated protein C resistance (APC-R) by the method of 'I34~hlb~c:~ (18); factor V Leiden by polymerase chain reaction (PCR) by the method of Dahlback (19) ; and functional fibrinogen assay by the method of Clauss (20). If all of these results were negative, the secondary panel consisted of plasminogen assay by chromogenic assay (21), plasminogen activator inhibitor Type I (PAI-1) (22), tissue plasminogen activator (t~PA) (23), heparin cofactor II (24), tissue factor pathway inhibitor (TFPI) (25) prothrombin gene G202IOA mutation by the method of Poort (26) , methylenetetrahydrofolate reductase (MTHFR) C677T mutation (27) , and fasting blood homocysteine levels (28) . All abnormal results, except PCR results, were repeated at least once for confirmation. Plasma heparin levels, for those patients placed on heparin, were obtained by anti-Xa assay (~''~}. Ctq and Ruji Cell assays were performed by methods of SLI (Specialty Laboratories, Santa Monica. CA). Antiphospholipid antibody subgroups (antiphosphatidytserine, aniiphosphatidylcholine, antiphosphatidylethanolamine. anti phosphatidy lalycerol, antiphosphatidylinositol, and antiphosphatidic acid), C lq, and Raji Cell immune com-plc~x assays were performed by ~p~ci4~lty Laboratories (Santa Monica, CA). All other special coagulation testing and platelet assays were performed by Thrombocare C<>~t~ci~~ti~~n Laboratories (Dallas, TX).
RESULTS
All patients, except two, demonstrated c~r~mplet~ healing within 3 months of starting therapy (range I U-9IJ days), and in four instances, patients and wound care managers noted healing within 7 to 14 days. Thus, with three months of therapy, 86.6% of patients were completely healed. Four of fifteen (26.6%) healed on clopidogrel alone, and l i of I5 (73.4%) required clopidogrel and dalteparin. One patient failing to _heal is patient #1. This patient is 32 years old and suffers from severe chronic venous insufficiency resulting from recurrent DVT episodes. He smoked four packs of cigarettes per day for the first 6 months of treatment, ignoring medical advice to stop. Now that smoking cessation has occurred, he is rapidiy healing at the time of this manuscript. The second patient, patient #2, is a 78-year-old female who has ~:r~Iiph~s~hc~Iipid syndrome and factor V Leiden (heterozygous), and suffers from severe chronic venous insufficiency ; she is slowly healing on medications.
The coagulation defects found were as followsi 13 of 15 patients (86.6%) have antiphospholipid thrombosis syndrome; the two patients without antiphospholipid thrombosis syndrome had immune vasculitis (positive Raji Cell immune complex assay and abnormal ~Iq~ and sticky platelet syndrome, Type I, and heterozygous factor V Leiden. Eleven of the fifteen patients ~?3.3~c~) had two procoagulant defects in hemostasis. and one had three independent defects (antiphospholipid thrombosis syndrome., tissue plasminogen activator deficiency, and PAI-I polymorphism). i The demographic characteristics and coagulation defects for each patient are found in Table 1. ) DISCUSSION ' Stasis ulcers are a major health care problem with substantial impact on quality of life. They also have a major impact on healthy care costs. Our preliminary re- '' suits suggest that if stasis ulcers do not heal quickly with edema control, compression therapy, routine wound care, and antibiotics, patients should be subjected to biopsy and a procoagulant hemostasis evaluation to assess the possibility of a blood coagulation protein/platelet or vascular problem leading to microvascular thrombosis, which prevents adequate blood supply for healing. If such a defect is found, the combination of clc~pidd~rel and dalteparin appears markedly effective in nli~~i~tin~ c ontinued microvascular occlusion and affords rapid ; wound healing. Enhancement of wound healing will not I only substantial impact quality of life for the patient, but it will also markedly impact patient health care costs. Clopidogrel is an excellent drug for these patients, not only because of the antiplatelet activity, which arises by inhibition of adenosine diphosphate-induced platelet aggregation (30), but also because of the beneficial effect this agent has on the vasculature (3 1). The low-molecular-weight heparin, dalteparin, is also an effective antithrombotic drug that is easy to administer at home by subcutaneous self-injection and is only given once a day. There are many advantages to this agent rather than other U.S. Food and Drug Administration-approved low-r~c~~~~ut~r-wei~~t heparins, including the high anti-Xa activity, lack of substantial bleeding, and advantageous anti-Xa/anti-Ha ratio (32) (33) (34) . No patient had a side effect to dalteparin. There were no cases of heparininduced thrombocytopenia (HIT/HITT), and no major or minor bleeding occurred. One patient had a minor side effect to clopidogrel (patient #3); this side effect was blurred vision. The blurred vision ceased when the dose was decreased to h~lf of a tablet (37.5 mg/day). In summary, it appears that patients with stasis utcers who do not heal appropriately with routine wound care measures are likely to have a procoagulant defect: this finding is not surprising, given many of those patients with stasis ulcers have developed the ulcers secondary to chronic venous insufficiency resulting from severe or long-term recurrent DVT. Our preliminary results also demonstrates that these patients, if they have a procoagutant defect, are likely to heal rapidly with combination pharmacologic therapy of clopidogrel and dalteparin.
